The US Food and Drug Administration declared that the risk of bleeding in patients who are new to Boehringer Ingelheim's blood-clot preventer Pradaxa is not higher than the currently used blood thinner warfarin. The FDA had earlier approved Ingelheim's Pradaxa for preventing strokes in patients who suffer from atrial fibrillation but safety concerns over the pill emerged following reports that it posed a risk for bleeding in patients who were newly introduced to the ...Saturday, 3 November 2012
FDA Allays Pradaxa Concerns
The US Food and Drug Administration declared that the risk of bleeding in patients who are new to Boehringer Ingelheim's blood-clot preventer Pradaxa is not higher than the currently used blood thinner warfarin. The FDA had earlier approved Ingelheim's Pradaxa for preventing strokes in patients who suffer from atrial fibrillation but safety concerns over the pill emerged following reports that it posed a risk for bleeding in patients who were newly introduced to the ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment